Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Brainstorm Cell Therapeutics stock
Learn how to easily invest in Brainstorm Cell Therapeutics stock.
Brainstorm Cell Therapeutics is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Brainstorm Cell Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – BCLI. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
Brainstorm Cell Therapeutics stock price (NASDAQ: BCLI)Use our graph to track the performance of BCLI stocks over time.
Brainstorm Cell Therapeutics shares at a glance
|Latest market close||$1.75|
|52-week range||$1.09 - $4.70|
|50-day moving average||$1.65|
|200-day moving average||$2.84|
|Wall St. target price||$7.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.64|
Buy Brainstorm Cell Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Brainstorm Cell Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Brainstorm Cell Therapeutics price performance over time
|1 week (2023-01-25)||20.34%|
|1 month (2022-12-30)||6.40%|
|3 months (2022-11-01)||-50.85%|
|6 months (2022-08-01)||-35.85%|
|1 year (2022-02-01)||-45.81%|
|2 years (2021-02-01)||-69.06%|
|3 years (2020-01-31)||4.07|
|5 years (2018-01-31)||3.48|
Brainstorm Cell Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-68.31%|
|Return on equity TTM||-193.43%|
|Market capitalisation||$53 million|
TTM: trailing 12 months
Brainstorm Cell Therapeutics share dividends
We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.
Have Brainstorm Cell Therapeutics's shares ever split?
Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.
Brainstorm Cell Therapeutics share price volatility
Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $1.0854 up to $4.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is -0.398. This would suggest that Brainstorm Cell Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Brainstorm Cell Therapeutics has bucked the trend.
Brainstorm Cell Therapeutics overview
Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics in the news
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer
Frequently asked questionsWhat percentage of Brainstorm Cell Therapeutics is owned by insiders or institutions?
Currently 22.696% of Brainstorm Cell Therapeutics shares are held by insiders and 10.617% by institutions. How many people work for Brainstorm Cell Therapeutics?
Latest data suggests 43 work at Brainstorm Cell Therapeutics. When does the fiscal year end for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's fiscal year ends in December. Where is Brainstorm Cell Therapeutics based?
Brainstorm Cell Therapeutics's address is: 1325 Avenue of Americas, New York, NY, United States, 10019 What is Brainstorm Cell Therapeutics's ISIN number?
Brainstorm Cell Therapeutics's international securities identification number is: US10501E2019 What is Brainstorm Cell Therapeutics's CUSIP number?
Brainstorm Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 10501E102
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert